logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for medical industry professionals · Thursday, July 31, 2025 · 835,772,195 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Lung Cancer News  •••  Topics  •  Countries  •  U.S. States

Chemotherapy & Lung Cancer News Monitoring

  • Published on Jul 30, 2025

    CLD-201 Receives FDA Fast Track Designation Targeting Sarcoma

    The investigational allogeneic adipose stem cell-loaded oncolytic virus, CLD-201 (SuperNova), has been granted fast track designation by the US FDA for the treatment of soft tissue sarcoma. This designation aims to expedite the development and review …

    Source: Targeted Oncology - Pending
  • Published on Jul 30, 2025

    How to Plan NSCLC Surgery Around Neoadjuvant Therapy

    Photo Credit: iStock.com/tomasworks At the 2025 ASCO Annual Meeting, a thoracic surgeon shared best practices for performing surgery on patients with NSCLC who have received neoadjuvant treatment. Presenters at the 2025 ASCO Annual Meeting offered …

    Source: Physician's Weekly - Neutral
  • Published on Jul 30, 2025

    Dr Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLC

    “With the intensive management of adverse [effects] required for treatment with amivantamab and lazertinib, and considering that both treatments are newer agents and not yet off patent, it is not surprising to see that amivantamab plus lazertinib was more …

    Source: OncLive - Pending
  • Published on Jul 30, 2025

    FDA Grants Fast Track Designation to Ateganosine for NSCLC

    The FDA has granted fast track designation to ateganosine (6-thio-dG or 6-thio-2’-deoxyguanosine; THIO) as a potential therapeutic option for patients with non–small cell lung cancer (NSCLC).1 Ateganosine is currently being evaluated in the phase 2 THIO- …

    Source: OncLive - Pending
  • Published on Jul 30, 2025

    FDA Grants Orphan Drug Status to VT3989 for Mesothelioma Treatment

    The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to VT3989 for the treatment of mesothelioma in the U.S., according to a news release from Vivace Therapeutics. VT3989 is an experimental cancer treatment that works by blocking …

    Source: Cure Today - Neutral
  • Published on Jul 30, 2025

    11 Best Future Stocks to Buy Now

    In this article, we will be taking a look at the 11 best future stocks to buy now. Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars. These patterns have made some wonder if …

    Source: Insider Monkey - Neutral
  • Published on Jul 30, 2025

    Sleep and Mesothelioma Cancer

    Sleep can be significantly affected by mesothelioma cancer, both physically and emotionally. Patients often struggle with sleep disturbances due to pain, shortness of breath, and coughing, especially at night when lying flat can worsen symptoms. Anxiety, …

    Source: Mesothelioma Hope - Pending
  • Published on Jul 30, 2025

    GSK suffers a setback with its TIM-3 programme

    GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer. In its second-quarter update this morning, GSK revealed …

    Source: pharmaphorum - Neutral
  • Published on Jul 30, 2025

    Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Call Transcript

    Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Call Transcript July 29, 2025 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $2.03. Operator: Thank you for standing by. Welcome to the Merck & Co., Inc., …

    Source: Insider Monkey - Neutral
  • Published on Jul 30, 2025

    How Charitable Giving Is Advancing Safer Cancer Treatments

    Millions of people are newly diagnosed with cancer each year, a word still likely to strike fear despite groundbreaking treatment. But what’s behind many of these medical miracles is a less tangible force: charitable giving. Around the world, donors are …

    Source: South Africa Today - Right-wing
  • Published on Jul 30, 2025

    Immune-Checkpoint Inhibitors in Lung Neuroendocrine Tumors – A Systematic Review and Meta-Analysis

    Introduction Lung neuroendocrine tumors (NETs) are well-differentiated epithelial neuroendocrine neoplasms (NENs) arising in the lung, which correspond to 30% of all NETs. These comprise typical carcinoids (TCs) and atypical carcinoids (ACs), regarded as …

    Source: Dove Medical Press - Neutral
  • Published on Jul 30, 2025

    EMA committee recommends approval of BeOne Medicines’ Tevimbra to treat neoadjuvant/adjuvant NSCLC

    BeOne Medicines Ltd., a global oncology company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of Tevimbra (tislelizumab), in combination with …

    Source: Pharmabiz.com - Neutral
  • Published on Jul 29, 2025

    Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

    A new real-world study found promising evidence for combining platinum-based chemotherapy with a programmed death-1 (PD-1) inhibitor, showing that the approach is both feasible and effective for patients with recurrent limited-disease small cell lung …

    Source: The American Journal of Managed Care - Neutral
  • Published on Jul 29, 2025

    Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

    For patients with advanced non–small cell lung cancer (NSCLC), treatment decisions have become increasingly dependent on the results of molecular testing. Comprehensive genomic profiling (CGP), which detects hundreds of potential genetic alterations in a …

    Source: Oncology Nursing News - Pending
  • Published on Jul 29, 2025

    3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and ...

    LEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: • Evaluate current and emerging clinical trial data on novel therapeutic strategies for the management of small cell lung cancer (SCLC) • Develop proactive …

    Source: Cancer Network - New Jersey - Pending
  • Published on Jul 29, 2025

    Trailblazing infantry veteran fights for life-saving cancer drug

    A Whanganui whānau is rallying behind their mother, a pioneering New Zealand Army veteran, as she battles Stage 4 lung cancer and seeks support for a life-saving medication not funded in New Zealand. Suzanne 'Su' Gingles made history in 1978 as one …

    Source: 1News - Neutral
  • Published on Jul 29, 2025

    Ateganosine Receives FDA Fast Track Designation for NSCLC

    MAIA Biotechnology’s investigational telomere-targeting agent, ateganosine (THIO, 6-thio-2’-deoxyguanosine, or 6-thio-dG), has been granted fast track designation by the US FDA for the treatment of advanced non–small cell lung cancer (NSCLC) that has …

    Source: Targeted Oncology - Pending
  • Published on Jul 29, 2025

    FDA Grants Priority Review to Imfinzi for Early Gastric Cancers

    A supplemental biologics license application for Imfinzi (durvalumab) has been accepted and granted priority review in the U.S. for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers, according to a …

    Source: Cure Today - Neutral
  • Published on Jul 29, 2025

    AstraZeneca’s Imfinzi granted FDA priority review to treat early-stage gastric cancer

    AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat early-stage gastric cancer. The decision specifically applies to patients with resectable, early-stage and locally advanced (stages 2, …

    Source: PMLiVE - Neutral

04 days 16:41:59

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more lung cancer news or search news using your own keywords. There are 835,772,195 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Lung Cancer News by Country >
Lung Cancer News by U.S. State >
Lung Cancer News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 07/17/2025

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Lung Cancer News Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow EIN Presswire on Facebook, LinkedIn and Substack

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2025 Newsmatics Inc. · All Rights Reserved · General Terms & Conditions · Privacy Policy

By continuing to use this site, you agree to our Terms & Conditions, last updated on July 21, 2025.

We use cookies to enhance your experience. Learn more